Archive: April 2025
Achieving Durable Response With the TRK Inhibitor Larotrectinib, and Possible Discontinuation of Therapy in Pediatric NTRK Gene Fusion–Positive Solid Tumors
In the Clinic: Case Studies In our clinic, the majority of pediatric patients presenting with neurotrophic tyrosine receptor kinase (NTRK) fusion–positive solid tumors are children diagnosed […]
Highlights in Renal Cell Carcinoma From the American Society of Clinical Oncology Genitourinary Cancers Symposium
A Review of Selected Presentations From the ASCO GU Symposium • February 13-15, 2025 • San Francisco, California Cabozantinib in Combination With Nivolumab and Ipilimumab in […]